News
FDA approves everolimus for tuberous sclerosis-associated seizures, a treatment first discovered at Texas Children’s Hospital
04/20/2018
On April 10, 2018, the Food and Drug Administration (FDA) approved everolimus tablets for oral suspension (brand name: Afinitor Dispersz, Novartis Pharmaceuticals Corporation) as an adjunctive therapy to treat partial-onset refractory seizures in adults and children over 2 years of age with Tuber
MoreFormer British Prime Minister shares the lessons he learnt from his son's rare epileptic syndrome
03/02/2018
David Cameron’s son Ivan was born with a neurological disorder that baffled doctors. He was later diagnosed with Ohtahara syndromea, rare epileptic syndrome. Now, he writes, genomic testing can end the anguish of uncertainty.
MoreA drug originally identified by Cain Lab researchers approved by EU for partial-onset seizures in Tuberous Sclerosis patients
12/05/2017
A drug initially discovered by the researchers in the Gordon and Mary Cain Foundation for Pediatric Neurology Research at Texas Children’s Hospital to be effective in treating refractory seizures commo
MoreDr. Wu Chen wins the 2017 American Epilepsy Society's Young Investigator Award
09/08/2017
Dr. Wu Chen selected for the 2017 American Epilepsy Society's Young Investigator Award.
MoreCDC finds an increase in epilepsy among Americans
08/16/2017
“Number of Americans with active epilepsy is increasing,” concludes a national and state-specific study that was published last week in the Center for Disease Control and Prevention (CDC)’s
More